Flow cytometric analysis of the graft-versus-leukemia-effect after hematopoietic stem cell transplantation in mice

Cytometry Part A

Volumn 87, Issue 4, 2015, Pages 334-345

  Schmidt, Felix ^a   Hilger, Nadja ^a   Oelkrug, Christoper ^a   Svanidze, Ellen ^a   Ruschpler, Peter ^a   Eichler, Wolfram ^b   Boldt, Andreas ^b   Emmrich, Frank ^a,b   Fricke, Stephan ^a,b  

^a FRAUNHOFER INSTITUTE FOR CELL THERAPY AND IMMUNOLOGY   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Bone marrow cells; Flow cytometry; Graft Versus Host Disease; Graft Versus Leukemia Effect; Hematopoietic stem cell transplantation; Triple transgenic mice

Indexed keywords

ANTIBODY; CD4 ANTIGEN; GREEN FLUORESCENT PROTEIN; HLA DR3 ANTIGEN; MONOCLONAL ANTIBODY;

ADVERSE EFFECTS; ALLOTRANSPLANTATION; ANIMAL; BAGG ALBINO MOUSE; BONE MARROW; BONE MARROW TRANSPLANTATION; C57BL MOUSE; CANCER TRANSPLANTATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SURVIVAL; CYTOLOGY; FLOW CYTOMETRY; GENETICS; GRAFT VERSUS LEUKEMIA EFFECT; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA; LIVER; MOUSE; PATHOLOGY; PROCEDURES; SPLEEN; TRANSGENIC MOUSE; TUMOR CELL LINE;

ANIMALS; ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTIGENS, CD4; BONE MARROW; BONE MARROW TRANSPLANTATION; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL SURVIVAL; FLOW CYTOMETRY; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; GREEN FLUORESCENT PROTEINS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA-DR3 ANTIGEN; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSION; LEUKEMIA; LIVER; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASM TRANSPLANTATION; SPLEEN; TRANSPLANTATION, HOMOLOGOUS;

EID: 84925355637     PISSN: 15524922     EISSN: 15524930     Source Type: Journal    
DOI: 10.1002/cyto.a.22619     Document Type: Article

References (58)

1. Ferrara JLM, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet 2009;373:1550-1561.
2. Garnett C, Apperley JF, Pavlu J. Treatment and management of graft-versus-host disease: Improving response and survival. Ther Adv Hematol 2013;4:366-378.
3. Kim J, Park K, Kim HJ, Kim J, Kim H-A, Jung D, Kim HJ, Choi H-J, Choi S-Y, Seo KW, et al. Breaking of CD8+ T cell tolerance through in vivo ligation of CD40 results in inhibition of chronic graft-versus-host disease and complete donor cell engraftment. J Immunol 2008;181:7380-7389.
4. Brochu S, Rioux-Massé B, Roy J, Roy DC, Perreault C. Massive activation-induced cell death of alloreactive T cells with apoptosis of bystander postthymic T cells prevents immune reconstitution in mice with graft-versus-host disease. Blood 1999;94:390-400.
5. Zeng Y, Stokes J, Hahn S, Hoffman E, Katsanis E. Activated MHC-mismatched T helper-1 lymphocyte infusion enhances GvL with limited GvHD. Bone Marrow Transplant 2014;49:1076-1083.
6. Kim Y-M, Sachs T, Asavaroengchai W, Bronson R, Sykes M. Graft-versus-host disease can be separated from graft-versus-lymphoma effects by control of lymphocyte trafficking with FTY720. J Clin Invest 2003;111:659-669.
7. Salomon B, Bluestone JA. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol 2001;19:225-252.
8. Bashey A, Medina B, Corringham S, Pasek M, Carrier E, Vrooman L, Lowy I, Solomon SR, Morris LE, Holland HK, et al. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood 2009;113:1581-1588.
9. Blazar BR, Taylor PA, Panoskaltsis-Mortari A, Sharpe AH, Vallera DA. Opposing roles of CD28:B7 and CTLA-4:B7 pathways in regulating in vivo alloresponses in murine recipients of MHC disparate T cells. J Immunol 1999;162:6368-6377.
10. Sprangers B, Fevery S, Van Wijmeersch B, De Somer L, Waer M, Billiau AD. Can graft-versus-leukemia reactivity be dissociated from graft-versus-host disease? Front Biosci 2007;12:4568-4594.
11. Shimoni A, Hardan I, Shem-Tov N, Yeshurun M, Yerushalmi R, Avigdor A, Ben-Bassat I, Nagler A. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: The role of dose intensity. Leukemia 2006;20:322-328.
12. Radich JP, Gooley T, Bensinger W, Chauncey T, Clift R, Flowers M, Martin P, Slattery J, Sultan D, Appelbaum FR. HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. Blood 2003;102:31-35.
13. Fricke S, Hilger N, Fricke C, Schönfelder U, Behre G, Ruschpler P, Boldt A, Oelkrug C, Sack U, Emmrich F. Prevention of graft-versus-host-disease with preserved graft-versus-leukemia-effect by ex vivo and in vivo modulation of CD4(+) T-cells. Cell Mol Life Sci 2014;71:2135-2148.
14. Fricke S, Ackermann M, Stolzing A, Schimmelpfennig C, Hilger N, Jahns J, Hildebrandt G, Emmrich F, Ruschpler P, Pösel C, et al. Allogeneic non-adherent bone marrow cells facilitate hematopoietic recovery but do not lead to allogeneic engraftment. PLoS ONE 2009;4:e6157.
15. Fricke S, Fricke C, Oelkrug C, Hilger N, Schönfelder U, Kamprad M, Lehmann J, Boltze J, Emmrich F, Sack U. Characterization of murine non-adherent bone marrow cells leading to recovery of endogenous hematopoiesis. Cell Mol Life Sci 2010;67:4095-4106.
16. Fricke S. Measurement and illustration of immune interaction after stem cell transplantation. Methods Mol Biol 2011;690:315-332.
17. Den Otter W, Maas RA, Koten JW, Dullens HF, Bernsen M, Klein WR, Rutten VP, Steerenberg PA, Balemans L, Ruitenberg EJ. Effective immunotherapy with local low doses of interleukin-2. In Vivo 1991;5:561-565.
18. Gajewski TF, Markiewicz MA, Uyttenhove C. The p815 mastocytoma tumor model. Curr Protoc Immunol 2001;43:20.4.1-20.4.18.
19. Bernstein ID, Wright PW, Cohen E. Generation of cytotoxic lymphocytes in vitro: Response of immune rat spleen cells to a syngeneic gross virus-induced lymphoma in mixed lymphocyte-tumor culture. J Immunol 1976;116:1367-1372.
20. Shoham J, Eshel I. Thymic hormonal effect on human peripheral blood lymphocytes in vitro. III. Conditions for mixed lymphocyte-tumor culture assay. J Immunol Methods 1980;37:261-272.
21. Muul LM, Gately MK. Hydrocortisone suppresses the generation of nonspecific "anomalous" killers but not specific cytolytic T lymphocytes in human mixed lymphocyte-tumor cultures. J Immunol 1984;132:1202-1207.
22. Uchida A, Klein E. Suppression of T-cell response in autologous mixed lymphocyte-tumor culture by large granular lymphocytes. J Natl Cancer Inst 1986;76:389-398.
23. Shigematsu Y, Hanagiri T, Shiota H, Kuroda K, Baba T, Ichiki Y, Yasuda M, Uramoto H, Takenoyama M, Yasumoto K, et al. Immunosuppressive effect of regulatory T lymphocytes in lung cancer, with special reference to their effects on the induction of autologous tumor-specific cytotoxic T lymphocytes. Oncol Lett 2012;4:625-630.
24. Ichino Y, Ishikawa T. Generation of human cytotoxic T lymphocytes against fresh autologous and allogeneic solid tumors by mixed lymphocyte tumor cell culture with T cell growth factor. Gann 1984;75:436-441.
25. Takao M, Takeda K. Enumeration, characterization, and collection of intact circulating tumor cells by cross contamination-free flow cytometry. Cytometry Part A 2011;79A:107-117.
26. Richards JO, Treisman J, Garlie N, Hanson JP, Oaks MK. Flow cytometry assessment of residual melanoma cells in tumor-infiltrating lymphocyte cultures. Cytometry Part A 2012;81A:374-381.
27. Fienberg HG, Simonds EF, Fantl WJ, Nolan GP, Bodenmiller B. A platinum-based covalent viability reagent for single-cell mass cytometry. Cytometry Part A 2012;81A:467-475.
28. Akagi J, Kordon M, Zhao H, Matuszek A, Dobrucki J, Errington R, Smith PJ, Takeda K, Darzynkiewicz Z, Wlodkowic D. Real-time cell viability assays using a new anthracycline derivative DRAQ7®. Cytometry Part A 2013;83A:227-234.
29. Fricke S, Rothe K, Hilger N, Ackermann M, Oelkrug C, Fricke C, Schönfelder U, Niederwieser D, Emmrich F, Sack U. Allogeneic bone marrow grafts with high levels of CD4+CD25+FoxP3+ T cells can lead to engraftment failure. Cytometry Part A 2012;81A:476-488.
30. Cooke KR, Hill GR, Gerbitz A, Kobzik L, Martin TR, Crawford JM, Brewer JP, Ferrara JL. Tumor necrosis factor-alpha neutralization reduces lung injury after experimental allogeneic bone marrow transplantation. Transplantation 2000;70:272-279.
31. Krishan A. Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining. J Cell Biol 1975;66:188-193.
32. Lim E, Modi KD, Kim J. In vivo bioluminescent imaging of mammary tumors using IVIS spectrum. J Vis Exp 2009;26:1210.
33. Demehri S, Corbin A, Loriaux M, Druker BJ, Deininger MW. Establishment of a murine model of aggressive systemic mastocytosis/mast cell leukemia. Exp Haematol 2006;34:284-288.
34. Peggs KS, Thomson K, Hart DP, Geary J, Morris EC, Yong K, Goldstone AH, Linch DC, Mackinnon S. Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: Toxicity, chimerism, and disease responses. Blood 2004;103:1548-1556.
35. Kolb H-J, Schmid C, Barrett AJ, Schendel DJ. Graft-versus-leukemia reactions in allogeneic chimeras. Blood 2004;103:767-776.
36. Johnson BD, Hanke CA, Truitt RL. The graft-versus-leukemia effect of post-transplant donor leukocyte infusion. Leuk Lymphoma 1996;23:1-9.
37. Porter DL, Antin JH. The graft-versus-leukemia effects of allogeneic cell therapy. Annu Rev Med 1999;50:369-386.
38. Xia G, Truitt RL, Johnson BD. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras. Biol Blood Marrow Transplant 2006;12:397-407.
39. Faber LM, van Luxemburg-Heijs SA, Willemze R, Falkenburg JH. Generation of leukemia-reactive cytotoxic T lymphocyte clones from the HLA-identical bone marrow donor of a patient with leukemia. J Exp Med 1992;176:1283-1289.
40. Boyer MW, Vallera DA, Taylor PA, Gray GS, Katsanis E, Gorden K, Orchard PJ, Blazar BR. The role of B7 costimulation by murine acute myeloid leukemia in the generation and function of a CD8+ T-cell line with potent in vivo graft-versus-leukemia properties. Blood 1997;89:3477-3485.
41. Mutis T, Verdijk R, Schrama E, Esendam B, Brand A, Goulmy E. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. Blood 1999;93:2336-2341.
42. Matulonis UA, Dosiou C, Lamont C, Freeman GJ, Mauch P, Nadler LM, Griffin JD. Role of B7-1 in mediating an immune response to myeloid leukemia cells. Blood 1995;85:2507-2515.
43. Dunussi-Joannopoulos K, Krenger W, Weinstein HJ, Ferrara JL, Croop JM. CD8+ T cells activated during the course of murine acute myelogenous leukemia elicit therapeutic responses to late B7 vaccines after cytoreductive treatment. Blood 1997;89:2915-2924.
44. Hirst WJ, Buggins A, Darling D, Gäken J, Farzaneh F, Mufti GJ. Enhanced immune costimulatory activity of primary acute myeloid leukaemia blasts after retrovirus-mediated gene transfer of B7.1. Gene Ther 1997;4:691-699.
45. Mutis T, Schrama E, Melief CJ, Goulmy E. CD80-Transfected acute myeloid leukemia cells induce primary allogeneic T-cell responses directed at patient specific minor histocompatibility antigens and leukemia-associated antigens. Blood 1998;92:1677-1684.
46. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, Rimm AA, Ringdén O, Rozman C, Speck B. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75:555-562.
47. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonck L, Niederwieser D, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995;86:2041-2050.
48. Blazar BR, Taylor PA, Linsley PS, Vallera DA. In vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice. Blood 1994;83:3815-3825.
49. Wallace PM, Johnson JS, MacMaster JF, Kennedy KA, Gladstone P, Linsley PS. CTLA4Ig treatment ameliorates the lethality of murine graft-versus-host disease across major histocompatibility complex barriers. Transplantation 1994;58:602-610.
50. Durie FH, Aruffo A, Ledbetter J, Crassi KM, Green WR, Fast LD, Noelle RJ. Antibody to the ligand of CD40, gp39, blocks the occurrence of the acute and chronic forms of graft-vs-host disease. J Clin Invest 1994;94:1333-1338.
51. Weiden PL, Flournoy N, Thomas ED, Prentice R, Fefer A, Buckner CD, Storb R. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 1979;300:1068-1073.
52. Sullivan KM, Weiden PL, Storb R, Witherspoon RP, Fefer A, Fisher L, Buckner CD, Anasetti C, Appelbaum FR, Badger C. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 1989;73:1720-1728.
53. Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S, Read EJ, Tisdale J, Dunbar C, Linehan WM, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000;343:750-758.
54. Raanani P, Dazzi F, Sohal J, Szydlo RM, van Rhee F, Reiter A, Lin F, Goldman JM, Cross NC. The rate and kinetics of molecular response to donor leucocyte transfusions in chronic myeloid leukaemia patients treated for relapse after allogeneic bone marrow transplantation. Br J Haematol 1997;99:945-950.
55. Warren EH, Deeg HJ. Dissecting graft-versus-leukemia from graft-versus-host-disease using novel strategies. Tissue Antigens 2013;81:183-193.
56. Newman RG, Ross DB, Barreras H, Herretes S, Podack ER, Komanduri KV, Perez VL, Levy RB. The allure and peril of hematopoietic stem cell transplantation: Overcoming immune challenges to improve success. Immunol Res 2013;57:125-139.
57. Alpdogan O, van den Brink MRM. Immune tolerance and transplantation. Semin Oncol 2012;39:629-642.
58. Alpdogan O. Advances in immune regulation in transplantation. Discov Med 2013;15:150-159.